Octapharma Reports - Industry Research
Reports Featuring Octapharma
Plasma Fractionation Market
The plasma fractionation market studied is anticipated to grow with a CAGR of nearly 8.76% during the forecast period.
Plasma Protein Therapeutics Market
The plasma protein therapeutics market has been projected to register a CAGR of 5.3% over the forecast period.
Immunoglobulin Market
The Global Immunoglobulin Market size is expected to grow from USD 14,482.11 million in 2023 to USD 20,607.86 million by 2028, at a CAGR of 7.31% during the forecast period.
Global Guillain-Barre Syndrome Market
The Guillain-Barre Syndrome Market studied is anticipated to grow at a CAGR of 5.2% during the forecast period, 2022-2027.
Global Fibrinogen Concentrate Market
The fibrinogen concentrate market is expected to register a healthy CAGR of 5.8% during the forecast period (2022-2027).
Von Willebrand Disease Treatment Market
The Von Willebrand disease (VWD) treatment market is expected to register a CAGR of 6.5% during the forecast period.
Antithrombin Market
The antithrombin market is expected to register a CAGR of 4.3% over the forecast period.
Anticoagulant Reversal Drugs Market
The anticoagulant reversal drugs market is expected to witness a CAGR of 12.01% over the forecast period.
Global Primary Immunodeficiency Therapeutics Market
The Primary Immunodeficiency Therapeutics Market is expected to register a CAGR of 6.1% during the forecast period.
Subcutaneous Immunoglobulin Market
The subcutaneous immunoglobulin market studied was projected to grow with a CAGR of nearly 13.3% over the forecast period.
Other Reports Covering Octapharma
Pharmaceuticals
- Albumin Market
- Anticoagulant Reversal Drugs Market
- Antithrombin Market
- Global Geriatric Medicines Market
- Global Guillain-Barre Syndrome Market
- Global Intravenous Immunoglobulin Market
- Global Primary Immunodeficiency Therapeutics Market
- Hemophilia Market
- Immunoglobulin Market
- Subcutaneous Immunoglobulin Market
- Thrombin Market
- Von Willebrand Disease Treatment Market
